Mass Spectrometry & Spectroscopy 21 Analysis of
Oligonucleotides and their Related Substances
Oligonucleotides are growing in importance in the pharmaceutical and biotechnology industries as
therapeutic medicines to address signifi cant medical needs that are so far unmet. Over the past decades, research into synthetic oligonucleotides as therapeutic medicines has grown as they have
the potential to be used as highly targeted medicines to treat a range of diseases, particularly genetic disorders.
However, oligonucleotides are a unique class of molecules and their structure and analysis make them one of the most challenging tasks for analytical chemists, and thus require a different approach to existing medicinal products.
For successful research and development, it is necessary to acquire new skills and knowledge in the fi eld of oligonucleotides analysis. This book, Analysis of Oligonucleotides and their Related Substances, provides various analytical technologies that are in frequent use in modern research and reviews the most up-to-date analytical strategies for synthetic oligonucleotides.
Subdivided into seven chapters, it discusses the importance of characterising impurities in oligonucleotides, the different chemical classes, and their synthetic origins. It also focuses on current analytical methodologies and strategies for characterising synthetic oligonucleotides using modern techniques in chromatography and spectroscopy. Readers are provided with a broad perspective and a wealth of current knowledge, while also being familiarised with actual instrumentation and case studies. This book will serve as an invaluable reference tool by giving guidance and tried-and-tested approaches for characterising oligonucleotides.
Available now in print or as an eBook. More information online:
ilmt.co/PL/e95E
55041pr@reply-direct.com Send your
Press Releases to:
pr@intlabmate.com
Collaboration to Optimise MS Data Analysis for Biopharmaceutical and Proteomics Applications Announced
Thermo Fisher Scientifi c and Protein Metrics have entered into a non-exclusive co-marketing agreement to provide advanced mass spectrometry data processing and analysis capabilities to drive innovation across the full spectrum of biopharmaceutical and proteomics applications, from research and development to quality control.
Thermo Fisher brings the cloud-enabled Thermo Scientifi c Chromeleon CDS software to this collaboration, providing biopharmaceutical and proteomics scientists with superior automation and workfl ow support to help achieve productivity gains of up to 33%. Easily integrated into company systems and seamlessly scaled from workstation to global enterprise deployment, the Chromeleon CDS software ensures business continuity. The software allows operation from remote locations across global laboratory networks, reducing administrative costs and providing resourcing fl exibility.
Supporting this collaboration, the Protein Metrics Byos platform for protein characterisation enables researchers to move from raw data fi les to reporting in just minutes, allowing post- translational modifi cations and other critical quality attributes to be monitored with speed and effi ciency. In addition, customers can also take advantage of Protein Metrics’ private- cloud Byosphere enterprise platform, which delivers enterprise-level capacity for automation, collaboration and data management in a single platform for GxP and non-GxP environments.
“Scientists undertaking biopharmaceutical and proteomics applications are challenged daily with having to accurately and reliably process a wealth of data derived from mass spectrometry instruments, which can be time-intensive and error-prone,” said Matt Hazlewood, Senior Director, Global Chromatography Data Systems, Thermo Fisher Scientifi c. “Our collaboration with Protein Metrics allows us to leverage our shared expertise and seamlessly integrate our compliance-ready software capabilities to offer customers fl exible tools that address these challenges and help meet their need for advanced technologies that analyse their mass spectrometry data.”
“We are proud that our proven biopharmaceutical solutions enable companies worldwide to analyse and report on complex biotherapeutics,” remarked Eric Carlson, PhD, President and CEO, Protein Metrics, Inc. “Byosphere, resting on Byos’ solid foundation, delivers to our users a single platform for GxP and non-GxP environments. Integrating with critical enterprise data systems, such as Chromeleon CDS, we aim to provide our mutual biopharmaceutical customers with intuitive, streamlined workfl ows to manage the burgeoning volume and complexity of analytical data with confi dence.”
More information online:
ilmt.co/PL/nJpL 54879pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196
